Myriad Genetics has entered into a five-year research agreement with Abbott Laboratories to identify new therapeutic targets. Myriad will use its genetics, RNA expression profiling and other discovery technologies to identify possible drug candidates. Abbott will be responsible for developing these candidates. "The combination of technologies achieved through this collaboration will further the drug discovery efforts at both companies and is expected to lead to innovative solutions for a wide range of unmet medical needs," said Dan Norbeck, Ph.D., Vice President, Pharmaceutical Discovery, Abbott. Terms of the deal were not disclosed.
- read this release for more
PLUS: AlphaRx and Proprius Pharmaceuticals today announced they have entered into a license agreement giving Proprius exclusive global rights to AlphaRx's topical NSAID, Indaflex, currently in Phase II trials for osteoarthritis. Release
ALSO: AdipoGenix and Unigen Pharmaceuticals have entered into an agreement for the joint discovery and development of natural products that target human fat. Report